Societal savings in patients with advanced non-squamous non-small-cell lung cancer receiving bevacizumab-based versus non-bevacizumab-based treatments in France, Germany, Italy, and Spain

BACKGROUND: The purpose of this study was to investigate the savings accrued using bevacizumab-based treatment for non-small-cell lung cancer from the societal perspective, taking only public costs into account, in France, Germany, Italy, and Spain. METHODS: Societal costs were estimated by collecting and analyzing labor costs, carer costs, sickness benefits, disability benefits, and home care benefits. Cost inputs were derived from publicly available databases or from the published literature. Expert opinion was only used if no other source was available. Efficacy data from two randomized clinical trials were used. The time horizon in the health economic model was lifetime. Efficacy and costs were discounted by 3.5%. All main model parameters were tested in deterministic and probabilistic sensitivity analyses. RESULTS: Mean incremental savings to society per patient ranged from €2277 in Italy to €4461 in Germany. The results were most sensitive to the change in proportion of patients working fulltime and the proportion of patients who were able to return to work. CONCLUSION: This analysis shows that bevacizumab-based treatment in non-small-cell lung cancer is associated with more savings to society compared to standard chemotherapy in terms of increased productivity and decreased social benefits paid to patients who are able to work in France, Germany, Italy, and Spain

Societal savings in patients with advanced non-squamous non-small-cell lung cancer receiving bevacizumab-based versus non-bevacizumab-based treatments in France, Germany, Italy, and Spain

Johanna Lister,1 Sanja Stanisic,1 Klaus Kaier,2 Christian Hagist,2 Dmitry Gultyaev,1 Stefan Walzer31Analytica LA-SER International Inc, Lörrach, Germany; 2Research Centre for Generational Contracts, University of Freiburg, Freiburg, Germany; 3F Hoffmann-La Roche Ltd, Pharmaceuticals Division, Basel, SwitzerlandBackground: The purpose of this study was to investigate the savings accrued using bevacizumab-based treatment for non-small-cell lung cancer from the societal perspective, taking only public costs into account, in France, Germany, Italy, and Spain.Methods: Societal costs were estimated by collecting and analyzing labor costs, carer costs, sickness benefits, disability benefits, and home care benefits. Cost inputs were derived from publicly available databases or from the published literature. Expert opinion was only used if no other source was available. Efficacy data from two randomized clinical trials were used. The time horizon in the health economic model was lifetime. Efficacy and costs were discounted by 3.5%. All main model parameters were tested in deterministic and probabilistic sensitivity analyses.Results: Mean incremental savings to society per patient ranged from €2277 in Italy to €4461 in Germany. The results were most sensitive to the change in proportion of patients working full-time and the proportion of patients who were able to return to work.Conclusion: This analysis shows that bevacizumab-based treatment in non-small-cell lung cancer is associated with more savings to society compared to standard chemotherapy in terms of increased productivity and decreased social benefits paid to patients who are able to work in France, Germany, Italy, and Spain.Keywords: non-small-cell lung cancer, bevacizumab, chemotherapy, economic model, France, Germany, Italy, Spai

The fiscal outlook in Austria: an evaluation with Generational Accounts

Fiscal sustainability, Generational accounting, Austria, Pension reform, Health care reform, H50, J10, H30,

Herausforderungen der Legislaturperiode für die Tragfähigkeit der Renten- und Pflegeversicherung

Die Nachwirkungen der Wirtschaftskrise und die Lasten der Konjunkturprogramme werden den Bund und die Länder bereits in dieser Legislaturperiode zu umfangreichen Konsolidierungsmaßnahmen zwingen, um das durch die Schuldenbremse gesteckte Ziel eines strukturell ausgeglichenen Haushalts zu erreichen. Das eigentliche Tragfähigkeitsproblem der öffentlichen Haushalte ist jedoch nach wie vor auf die Folgen der demografischen Entwicklung für die Finanzen der umlagefinanzierten Sozialversicherungen zurückzuführen. Vor diesem Hintergrund untersucht der vorliegende Beitrag, welchen Herausforderungen sich die schwarz-gelbe Regierungskoalition in der laufenden Legislaturperiode stellen muss, um die Tragfähigkeit der gesetzlichen Rentenversicherung und der sozialen Pflegeversicherung zu gewährleisten. Abstract The aftermath of the economic crisis and the burden of the fiscal stimulus packages call for considerable consolidation efforts by federal and state governments to meet the goal of a structurally balanced budget as required by the German debt brake in the medium-run. However, the real challenge for the sustainability of Germany's public finances is still to be found in the consequences of demographic transition for the financial stability of Germany's mandatory social insurance schemes. For this reason, the present paper addresses the challenges faced by the newly elected German government in the current legislative period to cope with the fiscal burden of population ageing for the sustainability of Germany's public pension and long-term care insurance schemes. JEL Classifications: H55, H60, H6

Pension System Solvency — From Linguistics to Economics

http://kotlikoff.net/articlesFirst author draf